PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q91067

Rena NISHIZAWA, et al.

Appln. No.: 10/554,096 Group Art Unit: 1625

Confirmation No.: 1876 Examiner: Rita J. DESAI

Filed: October 21, 2005

For: NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required. However, since a statement can be made, a statement is submitted herewith.

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

U.S. Appln. No.: 10/554,096

Attorney Docket No.: Q91067

the foreign language listed WO-A1-2004-026873 document, Applicant encloses herewith a copy

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

of a Communication from a foreign patent office (Supplementary European Search Report dated

June 19, 2008) in a counterpart application citing it, indicating the degree of relevance found by

the foreign patent office. Also, an English language abstract, submitted herewith, constitutes a

concise statement of relevance for WO-A1-2004-026873.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge the statutory fee of and all required

fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please

also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: July 29, 2008

/markboland/

Mark Boland

Registration No. 32,197

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q91067

Rena NISHIZAWA, et al.

Appln. No.: 10/554,096 Group Art Unit: 1625

Confirmation No.: 1876 Examiner: Rita J. DESAI

Filed: October 21, 2005

For: NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USE THEREOF

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

/markboland/

SUGHRUE MION, PLLC Mark Boland

Telephone: (202) 293-7060 Registration No. 32,197 Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: July 29, 2008